查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020643

2026-2034年特發性血小板減少紫斑症（ITP）治療藥物全球市場規模、佔有率、趨勢和成長分析報告

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

特發性血小板減少紫斑症(ITP) 治療的市場規模預計將從 2025 年的 7.4195 億美元成長到 2034 年的 12.1571 億美元，2026 年至 2034 年的複合年成長率為 5.64%。

隨著全球對自體免疫血液疾病的認知和診斷水準不斷提高，特發性血小板減少紫斑症（ITP）的治療市場也不斷擴大。 ITP是一種以血小板數量下降為特徵的疾病，可導致過度瘀傷和出血。診斷技術的進步和醫療基礎設施的改善使醫生能夠更有效地識別該疾病，從而導致對有效治療方法的需求日益成長。

多種因素正在推動ITP治療市場的成長，其中包括創新治療方法和標靶治療的開發。製藥公司正大力投資研發，以開發療效更佳、副作用更少的藥物。此外，生物製藥和免疫療法的日益普及也正在改善慢性ITP患者的治療效果。

未來，由於對罕見疾病研究投入的增加和生物技術的進步，市場預計將進一步擴張。隨著新療法的引入和患者管理策略的改進，治療的可及性有望得到提升。此外，新興國家政府的支持措施和不斷成長的醫療保健支出也將促進ITP治療市場的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球特發性血小板減少紫斑症(ITP) 治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 急性血小板減少性紫斑
  • 慢性血小板減少性紫斑

第5章 全球特發性血小板減少紫斑症(ITP) 治療市場：依產品分類

  • 市場分析、洞察與預測
  • 皮質類固醇
  • 靜脈注射免疫球蛋白（IVIG）
  • 血小板生成素受體促效劑（TPO-RAs）
  • 其他產品

第6章特發性血小板減少紫斑症（ITP）治療藥物的全球市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物

第7章 全球特發性血小板減少紫斑症(ITP) 治療市場：依年齡層分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人
  • 老年人

第8章 全球特發性血小板減少紫斑症(ITP) 治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 全球特發性血小板減少紫斑症(ITP) 治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Amgen
    • CSL Behring
    • F. Hoffmann La Roche
    • GlaxoSmithKline
    • Grifols
    • Intas Pharmaceuticals
    • Kedrion Biopharma
    • Novartis
    • Octapharma AG
    • Sobi
簡介目錄
Product Code: VMR112116960

The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market size is expected to reach USD 1215.71 Million in 2034 from USD 741.95 Million (2025) growing at a CAGR of 5.64% during 2026-2034.

The Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is growing as awareness and diagnosis of autoimmune blood disorders continue to increase worldwide. ITP is a condition characterized by low platelet counts, which can lead to excessive bruising and bleeding. Advances in diagnostic technologies and improved healthcare infrastructure are helping physicians identify the disease more effectively, thereby increasing demand for effective treatment options.

Several factors are driving the growth of the ITP therapeutics market, including the development of innovative treatment approaches and targeted therapies. Pharmaceutical companies are investing heavily in research and development to create more effective drugs with fewer side effects. Additionally, the increasing adoption of biologics and immunotherapies is improving treatment outcomes for patients with chronic ITP.

In the future, the market is expected to expand further due to growing investments in rare disease research and advancements in biotechnology. The introduction of novel therapeutic agents and improved patient management strategies will likely enhance treatment accessibility. Moreover, supportive government initiatives and rising healthcare spending in emerging economies will contribute to the long-term growth of the ITP therapeutics market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

  • Acute thrombocytopenic purpura
  • Chronic thrombocytopenic purpura

By Product

  • Corticosteroids
  • Intravenous immunoglobulins (IVIG)
  • Thrombopoietin receptor agonists (TPO-RA)
  • Other products

By Route of Administration

  • Oral
  • Injectable

By Age Group

  • Pediatric
  • Adult
  • Geriatric

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

COMPANIES PROFILED

  • Amgen, CSL Behring, F Hoffmann La Roche, GlaxoSmithKline, Grifols, Intas Pharmaceuticals, Kedrion Biopharma, Novartis, Octapharma AG, Sobi
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease Type
  • 4.2. Acute thrombocytopenic purpura Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Chronic thrombocytopenic purpura Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Intravenous immunoglobulins (IVIG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Thrombopoietin receptor agonists (TPO-RA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Age Group
  • 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Disease Type
    • 9.2.2 By Product
    • 9.2.3 By Route Of Administration
    • 9.2.4 By Age Group
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Disease Type
    • 9.3.2 By Product
    • 9.3.3 By Route Of Administration
    • 9.3.4 By Age Group
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Disease Type
    • 9.4.2 By Product
    • 9.4.3 By Route Of Administration
    • 9.4.4 By Age Group
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Disease Type
    • 9.5.2 By Product
    • 9.5.3 By Route Of Administration
    • 9.5.4 By Age Group
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Disease Type
    • 9.6.2 By Product
    • 9.6.3 By Route Of Administration
    • 9.6.4 By Age Group
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Amgen
    • 11.2.2 CSL Behring
    • 11.2.3 F. Hoffmann La Roche
    • 11.2.4 GlaxoSmithKline
    • 11.2.5 Grifols
    • 11.2.6 Intas Pharmaceuticals
    • 11.2.7 Kedrion Biopharma
    • 11.2.8 Novartis
    • 11.2.9 Octapharma AG
    • 11.2.10 Sobi